TP53BP1 and head and neck cancer: At 0.5 h after the first RT fraction, we found a 10-fold rise in the 53BP1 foci number in head and neck cancer patient samples (3.54 ± 0.46 53BP1 foci/cell) and rectal cancer patient samples (3.17 ± 0.40 53BP1 foci/cell).